Real ‐world treatment patterns and clinical outcomes in advanced cutaneous melanoma patients in France

ConclusionRegardless of the BRAF mutation status, the median OS of patients was 16 months (95% CI = 14–18). Compared to a similar study conducted in 2007 (MELODY), a gain of 4 months is observed. The gain seems to be higher for patients with a BRAF mutation (18 months) than for those without a BRAF mutation (14 months). The OS of patients who sequentially received both a BRAF inhibitor and ipilimumab (28 months) highlights the benefit of this treatment sequence.

Source: Journal of the European Academy of Dermatology and Venereology - October 17, 2017 Category: Dermatology Authors: B. Sassolas, M.T. Leccia, C. Godard, L. Benmahamed, A. Flinois, L. Levy ‐Bachelot, C. Bédane Tags: Original Article Source Type: research